Disease Detection International Inc. said it has received Food and Drug Administration approval to begin marketing a pregnancy test based on a technology that is at the root of a dispute between the Irvine-based company and its former parent, Environmental Diagnostics Inc.
The test--which can be performed in doctors' offices, hospitals or medical labs--is one of five DDI diagnostic tests that will be marketed for the next five months by the Du Pont Co. under an interim distribution agreement expected to bring DDI about $500,000 in sales through December.
All five of the tests are based on what DDI says is a new technology that it developed.
Environmental Diagnostics, however, maintains that DDI's process is merely an improvement of a technology that DDI has used under license from Environmental Diagnostics. The North Carolina firm has launched a proxy contest in which it is seeking to replace all five current DDI directors.
While that contest continues, Environmental Diagnostics alleges that DDI has no right to market products.
A spokesman for Du Pont said the marketing agreement with DDI has not been affected by the dispute with Environmental Diagnostics.